Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025

Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Feb 18, 2026

Immunocore (IMCR) Upgraded to Strong Buy: Here's Why

Immunocore (IMCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Feb 17, 2026

Immunocore announces R&D leadership evolution

Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Jan 30, 2026

Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock?

Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research • Jan 22, 2026

Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications – TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp combinations in ovarian and lung cancer and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be presented in 2H 2026 Planning to dose first patient in Phase 1 type 1 diabetes trial in 1H 2026 and to submit clinical trial application for second autoimmune candidate in 2H 2026 Company to present at 44 th Annual J.P.

GlobeNewsWire • Jan 9, 2026

Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Jan 8, 2026

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Nov 10, 2025

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the surface of infected hepatocytes (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Nov 7, 2025

Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst

Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline.

Seeking Alpha • Nov 8, 2025